1	Transcription	Transcription	_	_	_	_	_	_	_
2	factor	factor	_	_	_	_	_	_	_
3	activation	activation	_	_	_	_	_	_	_
4	in	in	_	_	_	_	_	_	_
5	lymphokine	lymphokine	_	_	_	_	_	_	_
6	activated	activated	_	_	_	_	_	_	_
7	killer	killer	_	_	_	_	_	_	_
8	cells	cell	_	_	_	_	_	_	_
9	and	and	_	_	_	_	_	_	_
10	lymphocytes	lymphocyte	_	_	_	_	_	_	_
11	from	from	_	_	_	_	_	_	_
12	patients	patient	_	_	_	_	_	_	_
13	receiving	receive	_	_	_	_	_	_	_
14	IL-2	il-2	_	_	_	_	_	_	_
15	immunotherapy	immunotherapy	_	_	_	_	_	_	_
16	.	.	_	_	_	_	_	_	_

1	Administration	Administration	_	_	_	_	_	_	_
2	of	of	_	_	_	_	_	_	_
3	the	the	_	_	_	_	_	_	_
4	cytokine	cytokine	_	_	_	_	_	_	_
5	interleukin-2	interleukin-2	_	_	_	_	_	_	_
6	(	(	_	_	_	_	_	_	_
7	IL-2	il-2	_	_	_	_	_	_	_
8	)	)	_	_	_	_	_	_	_
9	can	can	_	_	_	_	_	_	_
10	result	result	_	_	_	_	_	_	_
11	in	in	_	_	_	_	_	_	_
12	therapeutic	therapeutic	_	_	_	_	_	_	_
13	benefits	benefit	_	_	_	_	_	_	_
14	for	for	_	_	_	_	_	_	_
15	individuals	individual	_	_	_	_	_	_	_
16	with	with	_	_	_	_	_	_	_
17	renal	renal	_	_	_	_	_	_	_
18	cell	cell	_	_	_	_	_	_	_
19	carcinoma	carcinoma	_	_	_	_	_	_	_
20	and	and	_	_	_	_	_	_	_
21	melanoma	melanoma	_	_	_	_	_	_	_
22	.	.	_	_	_	_	_	_	_

1	Here	here	_	_	_	_	_	_	_
2	we	we	_	_	_	_	_	_	_
3	report	report	_	_	_	_	_	_	_
4	an	an	_	_	_	_	_	_	_
5	analysis	analysis	_	_	_	_	_	_	_
6	of	of	_	_	_	_	_	_	_
7	the	the	_	_	_	_	_	_	_
8	transcription	transcription	_	_	_	_	_	_	_
9	factor	factor	_	_	_	_	_	_	_
10	families	family	_	_	_	_	_	_	_
11	AP-1	ap-1	_	_	_	_	_	_	_
12	,	,	_	_	_	_	_	_	_
13	Sp1	Sp1	_	_	_	_	_	_	_
14	,	,	_	_	_	_	_	_	_
15	NF-kappaB	NF-kappaB	_	_	_	_	_	_	_
16	,	,	_	_	_	_	_	_	_
17	and	and	_	_	_	_	_	_	_
18	signal	signal	_	_	_	_	_	_	_
19	transducers	transducer	_	_	_	_	_	_	_
20	and	and	_	_	_	_	_	_	_
21	activators	activator	_	_	_	_	_	_	_
22	of	of	_	_	_	_	_	_	_
23	transcription	transcription	_	_	_	_	_	_	_
24	(	(	_	_	_	_	_	_	_
25	STAT	STAT	_	_	_	_	_	_	_
26	)	)	_	_	_	_	_	_	_
27	in	in	_	_	_	_	_	_	_
28	cancer	cancer	_	_	_	_	_	_	_
29	patients	patient	_	_	_	_	_	_	_
30	â€™	'	_	_	_	_	_	_	_
31	lymphocytes	lymphocyte	_	_	_	_	_	_	_
32	before	before	_	_	_	_	_	_	_
33	and	and	_	_	_	_	_	_	_
34	after	after	_	_	_	_	_	_	_
35	IL-2	il-2	_	_	_	_	_	_	_
36	immunotherapy	immunotherapy	_	_	_	_	_	_	_
37	,	,	_	_	_	_	_	_	_
38	as	as	_	_	_	_	_	_	_
39	assessed	assess	_	_	_	_	_	_	_
40	by	by	_	_	_	_	_	_	_
41	a	a	_	_	_	_	_	_	_
42	gel-shift	gel-shift	_	_	_	_	_	_	_
43	assay	assay	_	_	_	_	_	_	_
44	.	.	_	_	_	_	_	_	_

1	An	an	_	_	_	_	_	_	_
2	in	in	_	_	_	_	_	_	_
3	vitro	vitro	_	_	_	_	_	_	_
4	surrogate	surrogate	_	_	_	_	_	_	_
5	of	of	_	_	_	_	_	_	_
6	IL-2	il-2	_	_	_	_	_	_	_
7	immunotherapy	immunotherapy	_	_	_	_	_	_	_
8	is	be	_	_	_	_	_	_	_
9	the	the	_	_	_	_	_	_	_
10	incubation	incubation	_	_	_	_	_	_	_
11	of	of	_	_	_	_	_	_	_
12	fresh	fresh	_	_	_	_	_	_	_
13	peripheral	peripheral	_	_	_	_	_	_	_
14	blood	blood	_	_	_	_	_	_	_
15	mononuclear	mononuclear	_	_	_	_	_	_	_
16	cells	cell	_	_	_	_	_	_	_
17	(	(	_	_	_	_	_	_	_
18	PBMC	PBMC	_	_	_	_	_	_	_
19	)	)	_	_	_	_	_	_	_
20	from	from	_	_	_	_	_	_	_
21	healthy	healthy	_	_	_	_	_	_	_
22	individuals	individual	_	_	_	_	_	_	_
23	in	in	_	_	_	_	_	_	_
24	IL-2	il-2	_	_	_	_	_	_	_
25	for	for	_	_	_	_	_	_	_
26	several	several	_	_	_	_	_	_	_
27	days	day	_	_	_	_	_	_	_
28	,	,	_	_	_	_	_	_	_
29	resulting	result	_	_	_	_	_	_	_
30	in	in	_	_	_	_	_	_	_
31	the	the	_	_	_	_	_	_	_
32	production	production	_	_	_	_	_	_	_
33	of	of	_	_	_	_	_	_	_
34	lymphokine-activated	lymphokine-activated	_	_	_	_	_	_	_
35	killer	killer	_	_	_	_	_	_	_
36	(	(	_	_	_	_	_	_	_
37	LAK	LAK	_	_	_	_	_	_	_
38	)	)	_	_	_	_	_	_	_
39	activity	activity	_	_	_	_	_	_	_
40	in	in	_	_	_	_	_	_	_
41	these	these	_	_	_	_	_	_	_
42	cultures	culture	_	_	_	_	_	_	_
43	.	.	_	_	_	_	_	_	_

1	One	one	_	_	_	_	_	_	_
2	purpose	purpose	_	_	_	_	_	_	_
3	of	of	_	_	_	_	_	_	_
4	this	this	_	_	_	_	_	_	_
5	study	study	_	_	_	_	_	_	_
6	was	be	_	_	_	_	_	_	_
7	to	to	_	_	_	_	_	_	_
8	describe	describe	_	_	_	_	_	_	_
9	the	the	_	_	_	_	_	_	_
10	profile	profile	_	_	_	_	_	_	_
11	of	of	_	_	_	_	_	_	_
12	transcription	transcription	_	_	_	_	_	_	_
13	factor	factor	_	_	_	_	_	_	_
14	activation	activation	_	_	_	_	_	_	_
15	in	in	_	_	_	_	_	_	_
16	these	these	_	_	_	_	_	_	_
17	different	different	_	_	_	_	_	_	_
18	populations	population	_	_	_	_	_	_	_
19	,	,	_	_	_	_	_	_	_
20	and	and	_	_	_	_	_	_	_
21	assess	assess	_	_	_	_	_	_	_
22	whether	whether	_	_	_	_	_	_	_
23	the	the	_	_	_	_	_	_	_
24	patterns	pattern	_	_	_	_	_	_	_
25	observed	observe	_	_	_	_	_	_	_
26	correlated	correlate	_	_	_	_	_	_	_
27	with	with	_	_	_	_	_	_	_
28	functional	functional	_	_	_	_	_	_	_
29	differences	difference	_	_	_	_	_	_	_
30	in	in	_	_	_	_	_	_	_
31	these	these	_	_	_	_	_	_	_
32	cells	cell	_	_	_	_	_	_	_
33	.	.	_	_	_	_	_	_	_

1	Prior	prior	_	_	_	_	_	_	_
2	to	to	_	_	_	_	_	_	_
3	in	in	_	_	_	_	_	_	_
4	vivo	vivo	_	_	_	_	_	_	_
5	IL-2	il-2	_	_	_	_	_	_	_
6	administration	administration	_	_	_	_	_	_	_
7	,	,	_	_	_	_	_	_	_
8	the	the	_	_	_	_	_	_	_
9	typical	typical	_	_	_	_	_	_	_
10	binding	binding	_	_	_	_	_	_	_
11	pattern	pattern	_	_	_	_	_	_	_
12	of	of	_	_	_	_	_	_	_
13	transcription	transcription	_	_	_	_	_	_	_
14	factors	factor	_	_	_	_	_	_	_
15	in	in	_	_	_	_	_	_	_
16	PBMC	PBMC	_	_	_	_	_	_	_
17	from	from	_	_	_	_	_	_	_
18	patients	patient	_	_	_	_	_	_	_
19	resembled	resemble	_	_	_	_	_	_	_
20	that	that	_	_	_	_	_	_	_
21	seen	see	_	_	_	_	_	_	_
22	in	in	_	_	_	_	_	_	_
23	fresh	fresh	_	_	_	_	_	_	_
24	PBMC	PBMC	_	_	_	_	_	_	_
25	from	from	_	_	_	_	_	_	_
26	healthy	healthy	_	_	_	_	_	_	_
27	individuals	individual	_	_	_	_	_	_	_
28	.	.	_	_	_	_	_	_	_

1	Over	over	_	_	_	_	_	_	_
2	a	a	_	_	_	_	_	_	_
3	3-week	3-week	_	_	_	_	_	_	_
4	course	course	_	_	_	_	_	_	_
5	of	of	_	_	_	_	_	_	_
6	IL-2	il-2	_	_	_	_	_	_	_
7	therapy	therapy	_	_	_	_	_	_	_
8	,	,	_	_	_	_	_	_	_
9	in	in	_	_	_	_	_	_	_
10	most	most	_	_	_	_	_	_	_
11	patients	patient	_	_	_	_	_	_	_
12	the	the	_	_	_	_	_	_	_
13	binding	binding	_	_	_	_	_	_	_
14	patterns	pattern	_	_	_	_	_	_	_
15	of	of	_	_	_	_	_	_	_
16	AP-1	ap-1	_	_	_	_	_	_	_
17	,	,	_	_	_	_	_	_	_
18	Sp1	Sp1	_	_	_	_	_	_	_
19	,	,	_	_	_	_	_	_	_
20	and	and	_	_	_	_	_	_	_
21	NF-kappaB	NF-kappaB	_	_	_	_	_	_	_
22	proteins	protein	_	_	_	_	_	_	_
23	changed	change	_	_	_	_	_	_	_
24	to	to	_	_	_	_	_	_	_
25	resemble	resemble	_	_	_	_	_	_	_
26	those	those	_	_	_	_	_	_	_
27	seen	see	_	_	_	_	_	_	_
28	in	in	_	_	_	_	_	_	_
29	PBMC	PBMC	_	_	_	_	_	_	_
30	activated	activate	_	_	_	_	_	_	_
31	by	by	_	_	_	_	_	_	_
32	IL-2	il-2	_	_	_	_	_	_	_
33	in	in	_	_	_	_	_	_	_
34	vitro	vitro	_	_	_	_	_	_	_
35	.	.	_	_	_	_	_	_	_

1	However	however	_	_	_	_	_	_	_
2	,	,	_	_	_	_	_	_	_
3	the	the	_	_	_	_	_	_	_
4	cells	cell	_	_	_	_	_	_	_
5	obtained	obtain	_	_	_	_	_	_	_
6	from	from	_	_	_	_	_	_	_
7	IL-2-treated	il-2-treated	_	_	_	_	_	_	_
8	patients	patient	_	_	_	_	_	_	_
9	did	do	_	_	_	_	_	_	_
10	not	not	_	_	_	_	_	_	_
11	have	have	_	_	_	_	_	_	_
12	low-level	low-level	_	_	_	_	_	_	_
13	constitutive	constitutive	_	_	_	_	_	_	_
14	expression	expression	_	_	_	_	_	_	_
15	of	of	_	_	_	_	_	_	_
16	STAT	STAT	_	_	_	_	_	_	_
17	binding	binding	_	_	_	_	_	_	_
18	factors	factor	_	_	_	_	_	_	_
19	as	as	_	_	_	_	_	_	_
20	did	do	_	_	_	_	_	_	_
21	LAK	LAK	_	_	_	_	_	_	_
22	cells	cell	_	_	_	_	_	_	_
23	.	.	_	_	_	_	_	_	_

1	When	when	_	_	_	_	_	_	_
2	these	these	_	_	_	_	_	_	_
3	patient	patient	_	_	_	_	_	_	_
4	cells	cell	_	_	_	_	_	_	_
5	were	be	_	_	_	_	_	_	_
6	further	further	_	_	_	_	_	_	_
7	stimulated	stimulate	_	_	_	_	_	_	_
8	by	by	_	_	_	_	_	_	_
9	IL-2	il-2	_	_	_	_	_	_	_
10	in	in	_	_	_	_	_	_	_
11	vitro	vitro	_	_	_	_	_	_	_
12	,	,	_	_	_	_	_	_	_
13	additional	additional	_	_	_	_	_	_	_
14	differences	difference	_	_	_	_	_	_	_
15	in	in	_	_	_	_	_	_	_
16	STAT	STAT	_	_	_	_	_	_	_
17	induction	induction	_	_	_	_	_	_	_
18	patterns	pattern	_	_	_	_	_	_	_
19	were	be	_	_	_	_	_	_	_
20	noted	note	_	_	_	_	_	_	_
21	.	.	_	_	_	_	_	_	_

1	These	these	_	_	_	_	_	_	_
2	data	datum	_	_	_	_	_	_	_
3	provide	provide	_	_	_	_	_	_	_
4	further	further	_	_	_	_	_	_	_
5	information	information	_	_	_	_	_	_	_
6	on	on	_	_	_	_	_	_	_
7	the	the	_	_	_	_	_	_	_
8	molecular	molecular	_	_	_	_	_	_	_
9	events	event	_	_	_	_	_	_	_
10	occurring	occur	_	_	_	_	_	_	_
11	in	in	_	_	_	_	_	_	_
12	immune	immune	_	_	_	_	_	_	_
13	cells	cell	_	_	_	_	_	_	_
14	generated	generate	_	_	_	_	_	_	_
15	through	through	_	_	_	_	_	_	_
16	in	in	_	_	_	_	_	_	_
17	vivo	vivo	_	_	_	_	_	_	_
18	and	and	_	_	_	_	_	_	_
19	in	in	_	_	_	_	_	_	_
20	vitro	vitro	_	_	_	_	_	_	_
21	administration	administration	_	_	_	_	_	_	_
22	of	of	_	_	_	_	_	_	_
23	IL-2	il-2	_	_	_	_	_	_	_
24	,	,	_	_	_	_	_	_	_
25	and	and	_	_	_	_	_	_	_
26	further	further	_	_	_	_	_	_	_
27	document	document	_	_	_	_	_	_	_
28	that	that	_	_	_	_	_	_	_
29	there	there	_	_	_	_	_	_	_
30	is	be	_	_	_	_	_	_	_
31	not	not	_	_	_	_	_	_	_
32	a	a	_	_	_	_	_	_	_
33	precise	precise	_	_	_	_	_	_	_
34	congruence	congruence	_	_	_	_	_	_	_
35	between	between	_	_	_	_	_	_	_
36	PBMC	PBMC	_	_	_	_	_	_	_
37	activated	activate	_	_	_	_	_	_	_
38	in	in	_	_	_	_	_	_	_
39	vivo	vivo	_	_	_	_	_	_	_
40	and	and	_	_	_	_	_	_	_
41	in	in	_	_	_	_	_	_	_
42	vitro	vitro	_	_	_	_	_	_	_
43	by	by	_	_	_	_	_	_	_
44	IL-2	il-2	_	_	_	_	_	_	_
45	.	.	_	_	_	_	_	_	_

